Patents Examined by Zohreh Vakili
-
Patent number: 8008458Abstract: This invention relates to a biologically active formulation containing a conjugate of a fatty acid and a complex phenol. The fatty acid can be selected from a variety of fatty acids including acids have between 12 and 24 carbon atoms. The phenol can be a polynuclear phenol, a polyphenol or a polyfunctional phenol having a variety of substituents. The formulation can include pharmaceutically acceptable carrier, including diluent. The formulation can be provided in an active dosage form suitable to inhibit mammalian cell growth and/or metastasis of malignant cells. The formulation can be used to induce cytotoxicity in mammalian cells particularly tumor cells or to treat and prevent cellular injury or dysfunction.Type: GrantFiled: March 27, 2007Date of Patent: August 30, 2011Assignee: Indiana University Health Inc.Inventors: Gary P. Zaloga, Rafat Siddiqui, William Stillwell
-
Patent number: 8003683Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.Type: GrantFiled: November 13, 2006Date of Patent: August 23, 2011Assignee: Signature R&D Holdings, LLCInventor: V. Ravi Chandran
-
Patent number: 7981916Abstract: Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea.Type: GrantFiled: December 17, 2007Date of Patent: July 19, 2011Assignee: Galderma S.A.Inventors: Claire Mallard, Alain Brzokewicz
-
Patent number: 7981445Abstract: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.Type: GrantFiled: March 11, 2009Date of Patent: July 19, 2011Assignee: Abraxis Bioscience, LLCInventors: Tapas De, Neil P. Desai, Andrew Yang, Zachary Yim, Patrick Soon-Shiong
-
Patent number: 7968588Abstract: A pharmaceutical composition for injection comprising a depsipeptide antibiotic, WAP-8294A2, as an active ingredient, which is stable and contains WAP-8294A2 in high concentrations is provided. This composition comprises WAP-8294A2 of the following structural formula (1) as an active ingredient and is characterized in that 2-hydroxypropyl-?-cyclodextrin or ?-cyclodextrin is contained as a stabilizer or solubilizer and the pH of the composition is not adjusted. This composition is mixed with a pH-adjusting agent such as dextrose and with an infusion or diluent comprising a solution of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium hydroxide at the time of use to prepare a solution for intravenous administration of WAP-8294A2.Type: GrantFiled: June 28, 2007Date of Patent: June 28, 2011Assignee: eRigen Pharmaceuticals, Inc.Inventors: Hirofumi Nakajima, Haruhiko Machida
-
Patent number: 7968085Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: GrantFiled: October 7, 2004Date of Patent: June 28, 2011Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Patent number: 7964638Abstract: The present invention is to provide skin cosmetics and anti-wrinkle agents which are excellent in reducing effect on wrinkle caused by photoaging. Skin cosmetics and anti-wrinkle agents which comprise isosorbide represented by the following formula (1).Type: GrantFiled: April 21, 2006Date of Patent: June 21, 2011Assignee: Kao CorporationInventors: Kyoko Miura, Akinori Haratake
-
Patent number: 7947262Abstract: Mast cell (MC) and peripheral blood basophil (PBB)-associated diseases are treated or prevented, or their symptoms are alleviated by the administration of water soluble fullerenes (buckeyballs) to the individual under conditions sufficient to inhibit MC and PBB responses. MC and PBB responses are associated with, for example, various allergies including Type 1 hypersensitivity initiated by IgE-antigen, arthritis, multiple sclerosis, urticaria, atopic dermatitis, heart disease, etc. The treatment regimen can be enhanced using Chimeric fullerenes that specifically home to and inhibit MC and PBB cells. These molecules, for example, comprise fullerenes to which are attached IgE Fc or stem cell factor (SCF) peptides that bind to receptors specifically on MC and PBB cells. Additional molecules which may be used in the processes include IgE Fc or SCF peptides with several fullerenes covalently attached.Type: GrantFiled: September 26, 2006Date of Patent: May 24, 2011Assignee: Virginia Commonwealth UniversityInventor: Chris Kepley
-
Patent number: 7943292Abstract: Artificial plasma-like solutions and methods for their use are provided. The subject solutions include: electrolytes and an oncotic agent. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.Type: GrantFiled: September 6, 2007Date of Patent: May 17, 2011Assignee: BioTime, Inc.Inventors: Paul E. Segall, Hal Sternberg, Harold D. Waitz, Judith M. Segall
-
Patent number: 7906107Abstract: The hair wax product with liquid or creamy consistency for treating or setting up a human hairstyle contains at least 40% by weight of an aqueous or aqueous-alcoholic carrier medium, at least 5 percent by weight of an emulsifier and at least 2 percent by weight of wax. The weight ratio of emulsifier to wax is greater than 1, preferably 1.1 to 4. The invention also includes methods for styling and re-styling human hair-dos or hairstyles using the hair wax product according to the invention.Type: GrantFiled: July 25, 2003Date of Patent: March 15, 2011Assignee: Wella AGInventors: Sarah Maillefer, Andre Rehmann, Benedikt Zenhaeusern
-
Patent number: 7892218Abstract: A formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5, comprising (a) 3-100% by weight of glycolide; (b) optionally 97-15% by weight of a solid organic acid; and (c) optionally 5-30% of a wetting agent. Also disclosed is a catamenial tampon for insertion in a human vagina which comprises the pH reducing formulation.Type: GrantFiled: March 3, 2004Date of Patent: February 22, 2011Assignee: Rostam Ltd.Inventors: Theodor Stern, Ram Kluger
-
Patent number: 7888346Abstract: A method of treating organophosphorous (OP) poisoning comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine.Type: GrantFiled: September 23, 2005Date of Patent: February 15, 2011Assignee: Universtiy of Maryland, BaltimoreInventors: Edson X. Albuquerque, Michael Adler, Edna F. R. Pereira
-
Patent number: 7867999Abstract: Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.Type: GrantFiled: December 19, 2006Date of Patent: January 11, 2011Assignee: Alcon Research, Ltd.Inventors: Hwang-Hsing Chen, Najam A. Sharif, Mark R. Hellberg
-
Patent number: 7862836Abstract: The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.Type: GrantFiled: April 12, 2006Date of Patent: January 4, 2011Assignee: Biolink Life Sciences, Inc.Inventor: Deanna Jean Nelson
-
Patent number: 7837649Abstract: The present invention provides a nasal clip including two parts which are both injection molded. The first part, the base with a holster cavity for the second piece, the scent bar, which is impregnated with an aromatic substance such as essential oils, or aromatic medications. The purpose of the holster cavity is to keep the scent bar away from the skin, since the oils can irritate the skin if in direct contact. The base is fashioned in a way with various openings in order to emit as much aroma as possible. The scent bar is formed of a porous material, such as a poly-olefin plastic that undergoes a process of impregnation on saturation with the aromatic substance. The concentration of each type of aromatic substance will determine the length of time the scent bar will be soaked with may range from as little as a few hours to as much as a week. The nature of the poly-olefin plastic is to naturally absorb up to 30% of the aromatic substance.Type: GrantFiled: November 7, 2005Date of Patent: November 23, 2010Inventor: Clifford S. Aboff
-
Patent number: 7795316Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.Type: GrantFiled: December 19, 2007Date of Patent: September 14, 2010Assignee: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra
-
Patent number: 7781459Abstract: The invention relates to acyl-carboxyphenylurea derivatives and to their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I, in which the radicals have the stated meanings, and the physiological tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example for the treatment of type II diabetes.Type: GrantFiled: December 20, 2006Date of Patent: August 24, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Elisabeth DeFossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger, Alfons Enhsen
-
Patent number: 7780977Abstract: A medicinal composition comprising: (a) a core comprising a medicinally effective unit dose of one or more active medicaments; and (b) said medicament(s) being enclosed within a film material which comprises at least 40% by weight hydroxypropylmethyl cellulose.Type: GrantFiled: June 11, 2002Date of Patent: August 24, 2010Assignee: Bioprogress Technology LimitedInventors: Andrew John Inchley, Kenneth Donald Vaughan
-
Patent number: 7767712Abstract: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.Type: GrantFiled: May 3, 2007Date of Patent: August 3, 2010Assignee: Verla-Pharm Arzneimittelfabrik Apotheker H.J.v. Ehrlich GmbH & Co. KGInventor: Günter Hopf
-
Patent number: 7708990Abstract: The object of the present invention is to provide a composition maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time, in order to surely attain an effect of coenzyme Q, which can be expected to manifest a superior effect in maintaining health in humans and animals. By using a composition which comprises a coenzyme Q being a mixture of a reduced coenzyme Q and an oxidized coenzyme Q with the proportion of the reduced coenzyme Q to the whole coenzyme Q of more than 95% by weight, the present invention can attain a high maximum blood concentration of a coenzyme Q as well as long maintenance of high concentration of coenzyme Q in blood for a prolonged period of time, and the area under the blood concentration curve (AUC) can be expanded.Type: GrantFiled: March 22, 2005Date of Patent: May 4, 2010Assignee: Kaneka CorporationInventors: Kenji Fujii, Taizo Kawabe, Hiroshi Kubo